|
|
ACLU/PUBPAT Gene Patent Challenge Moves Ahead
- 4 Hours ago
|
|
|
|
A federal district court said that the ACLU et al. suit challenging the patentability of gene patents can go forward. The American Civil Liberties Union (ACLU), the Public Patent Foundation (PUBPAT),
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
State to subsidize biotech investment funds
- 4 Hours ago
|
|
|
|
The state will try to repeat its success in high-tech investing by establishing joint public-private funds for Israeli biotech investments. The Industry, Trade and Labor Ministry and the Finance Ministry
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Nanoparticles for gene therapy improve
- 98 Minutes ago
|
|
|
|
About five years ago, Professor Janet Sawicki at the Lankenau Institute in Pennsylvania read an article about nanoparticles developed by MIT's Daniel Anderson and Robert Langer for gene therapy, the insertion
|
|
|
|
|
|
|
|
|
|
|
|
|
DNA Molecules In Moss Open Door To New Biotechnology
- 107 Minutes ago
|
|
|
|
Plasmids, which are DNA molecules capable of independent replication in cells, have played an important role in gene technology. Researchers from Uppsala University in Sweden have now demonstrated that
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Biometrics: enhancing security or invading privacy?
- 4 Hours ago
|
|
|
|
The Irish Council for Bioethics (ICB) has launched its report entitled 'Biometrics: Enhancing Security or Invading Privacy?' The report advises that these technologies, though powerful, must be used appropriately
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
New gene therapy halts 2 boys' rare brain disease
- 4 Hours ago
|
|
|
|
WASHINGTONFrench scientists mixed gene therapy and bone marrow transplants in two boys to seemingly halt a brain disease that can kill by adolescence. The surprise ingredient: They disabled the HIV virus
|
|
|
|
|
|
|
|
|
|
|
|
|
Elan, Biogen change Tysabri label due to PML risk
- 13 Hours ago
|
|
|
|
3:34pm GMT storyKeywords RTR_ArticleTitle 'Elan, Biogen change Tysabri label due to PML RTR_ArticleBlurb ' DUBLIN, Nov 7 (Reuters) Ireland's Elan (ELN.I) and U.S. drugmaker Biogen Idec (BIIB.O) have amended
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
There is paucity of data pertaining to GM food
- 9 Hours ago
|
|
|
|
MYSORE: A conference on Genetic engineering, farming and food held here on Saturday discussed the science behind genetically modified (GM) crops and examined their ramifications on food security, environment
|
|
|
|
|
|
|
|
|
|
|
|
|
New label says Tysabri risks increase over time
- 18 Hours ago
|
|
|
|
NEW YORK - A brain infection linked to Biogen Idec Inc. and Elan Corp.â??s Tysabri is more likely to occur the longer patients use the multiple sclerosis drug, new prescribing information says.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Local biotech firm wins OK on cancer drug
- 23 Hours ago
|
|
|
|
Gloucester Pharmaceuticals, a six-year-old Cambridge biotechnology start-up, has won approval from the Food and Drug Administration to market its first drug in the United States. The drug, called Istodax,
|
|
|
|
|
|
|
|
|
|
|
|
|
A third quarter improvement for biotech hiring
- 11/7/2009
|
|
|
|
Mitogen-activated protein kinases(MAPK) are activated in response to extracellularsignals or cellular stress. We have set up a cell-based DELFIA®Time-Resolved Fluorescence assay to test compounds or
|
|
|
|
|
|
|
|
|
|
|
|
|
Threshold Pharmaceuticals 3Q loss widens on costs
- 11/6/2009
|
|
|
|
Threshold Pharmaceuticals Inc., a development-stage biotechnology company, said late Thursday its third-quarter loss widened on higher research, development, and interest expenses. The company lost $6.2
|
|
|
|
|
|
|
|
|
|
|
|
*Votes may take up to 30 minutes to influence
article rank order |
|